Microbiome Hype Meets Epilepsy: Signal,Noise,and Mechanism

Abstract

Gut–Brain Cholinergic Signaling Mediates the Antiseizure Effects of Bacteroides fragilis

Jia Y, Chen H, Zou Q, Chen S, Li J, Chen Y, Lu L, Hong F, Jia S, Jing X, Ren J, Muhammad F, Mi J, Duan J, Liao J, Liu Q, Xu F, Kenny PJ, Han MH, Wang L, Chen Z, Cao D, Liu XA. Neuron. 2026; 114(6): 1021-1044.e9. doi:10.1016/j.neuron.2025.11.029. Epub 2026 Jan 16. PMID: 41547348.

Gut dysbiosis has been implicated in epilepsy, yet probiotic efficacy and mechanisms remain unclear. Here, we identify that Bacteroides fragilis (B. fragilis) is markedly reduced in children with epilepsy and show that oral B. fragilis administration suppresses seizures in both pentylenetetrazole- and kainic-acid-induced mouse models. Mechanistically, B. fragilis activates colonic choline acetyltransferase-positive (ChAT⁺) cells and enhances gut–vagus–brain cholinergic signaling, as demonstrated by vagal recordings, pharmacological blockade, and chemogenetic manipulation, identifying a colonic ChAT⁺-nodose ganglion circuit mediating seizure suppression. Its antiseizure effects associate with enriched intestinal Lactobacillus colonization. A randomized clinical trial (CHiCTR2100042203) further confirms the therapeutic efficacy of B. fragilis in pediatric refractory epilepsy. These findings define a gut–brain cholinergic pathway through which B. fragilis exerts antiseizure effects and establish a mechanistic basis for microbiota-targeted therapies in epilepsy.

Gut dysbiosis (an imbalance in the gut microbiota) has been associated with a wide range of diseases, including inflammatory, metabolic, and neurological disorders such as autism, depression, and anxiety. However, these associations remain controversial, with increasing pushback against overstated causal claims and calls for more rigorous study designs to establish causality. ¹ In this context, Jia et al (2026) ² report a potential link between gut microbiota and epilepsy in children, highlighting reduced levels of Bacteroides fragilis (B. fragilis) as a possible contributing factor. This study is compelling in that it shifts part of epilepsy biology beyond the brain, pointing to a potentially modifiable, noninvasive therapeutic avenue grounded in a defined gut–brain pathway. With further validation in clinical populations, these findings could open a new therapeutic space, including adjunct microbiome-based interventions alongside existing antiseizure medications, as well as possible preventive strategies in at-risk populations.

To characterize microbiota alterations, Jia et al performed 16S rRNA sequencing on fecal samples from 114 patients with newly diagnosed pediatric epilepsy (NDPE) and 63 healthy controls. NDPE patients showed increased relative abundance of Actinobacteriota (eg, Bifidobacterium) and Verrucomicrobiota (notably Akkermansia muciniphila), taxa often associated with improved gut barrier function and metabolic health.^3,4 In contrast, the phylum Bacteroidota, which includes the genera Bacteroides, Parabacteroides, and Prevotella, as well as the species B. fragilis, was decreased. Among these taxa, Bacteroides and Parabacteroides levels were reduced in NDPE patients relative to controls, whereas Prevotella levels were unchanged and B. fragilis was not reported. Metagenomic sequencing on fetal samples from 39 healthy controls and 37 children with refractory epilepsy also revealed differences in gut microbial composition between the 2 groups, including a significant reduction in the abundance of B. fragilis in the children with refractory epilepsy compared to controls, but no significant differences in the relative abundance of Bacteroides.

Reduced B. fragilis is not inherently detrimental, and in some contexts has been associated with improved metabolic profiles. ⁵ Importantly, it remains unclear whether these microbiota changes reflect disease-specific mechanisms or secondary effects of treatment and lifestyle. Many children with refractory epilepsy are treated with a ketogenic diet, which alters metabolism, gut microbiota composition, and host physiology. Thus, reductions in B. fragilis may reflect dietary or pharmacological effects rather than epilepsy itself. Moreover, as B. fragilis abundance was not reported in the NDPE cohort and was assessed only in refractory epilepsy, conclusions regarding its specificity across disease stages remain limited.

Jia et al further provide preclinical evidence that BF839, a commercially available B. fragilis probiotic, may exert anticonvulsant effects. In mouse models of PTZ-induced seizures and kindling, BF839 reduced seizure frequency and severity and attenuated hippocampal hyperexcitability, as indicated by decreased spike-wave discharge activity and reduced EEG power in theta, alpha, and beta bands. Similar effects were observed in a kainic acid-induced seizure model, suggesting a broader impact on neuronal excitability.

Translational relevance is suggested by a small clinical study (n = 20 placebo; n = 25 BF839; ages 0-14 years), in which BF839 supplementation alongside standard therapy resulted in a higher response rate compared to placebo (32% vs. 5%), suggesting efficacy. However, responses were heterogeneous, with greater benefit observed in non-Dravet syndrome patients. Notably, microbiota changes, specifically increases in Bacteroides and Lactobacillus, were observed only in the non-Dravet group. This weakens the specificity of the findings to treatment-resistant epilepsy and complicates the interpretation of a direct microbiota-mediated mechanism. Accordingly, the link between microbial shifts and seizure outcomes remains correlative.

Mechanistically, the authors propose that BF839 acts via modulation of vagal nerve signaling. The vagus nerve plays a central role in gut–brain communication, and BF839 increased spontaneous vagal firing in mice. Interestingly, this effect appeared biphasic: an early phase independent of nicotinic acetylcholine receptor signaling, and a later phase dependent on nicotinic transmission. This suggests that early signaling could involve alternative mediators such as serotonin, ATP, peptides, or immune-derived signals. While the authors further propose that ChAT⁺ tuft cells form synaptic connections with vagal afferents, enabling direct cholinergic signaling, this mechanism requires stronger anatomical and functional validation.

More convincingly, BF839-induced vagal activation was associated with altered neural activity in central circuits, including increased c-Fos expression in subregions of the nucleus tractus solitarius (NTS) and decreased activity in hippocampal regions (CA3 and dentate gyrus). These findings support a gut–vagus–brain pathway, although the precise circuit linking NTS activity to hippocampal excitability remains to be defined.

Interestingly, vagus nerve stimulation (VNS) is an established adjunct therapy for refractory epilepsy, with approximately 30% to 50% of patients achieving ≥50% seizure reduction over time. ⁶ This raises the possibility that microbiota-based interventions such as BF839 could augment VNS efficacy. However, in preclinical models, combining BF839 with VNS did not significantly decrease seizure frequency or severity compared to BF839 alone, although seizure duration was notably reduced. These findings suggest modest additive effects, though further clinical validation is needed.

Results from antibiotic-mediated depletion of the gut microbiota in Jia et al challenge a simple “microbiome → seizures” model. Despite substantial shifts in microbial composition, including reduced Bacteroidota and increased Proteobacteria, a phylum that includes potentially pathogenic genera such as Escherichia, Salmonella, Helicobacter, Vibrio, and Klebsiella and is often associated with dysbiosis, ⁷ PTZ-induced seizure outcomes were not worsened. In fact, trends toward reduced seizure frequency and severity were observed. In the context of PTZ-induced seizures, both antibiotic treatment and BF839 also increased expression of tight junction proteins (ZO-1 and occludin) relative to PTZ treatment alone, suggesting partial restoration of barrier integrity. These findings indicate that broad microbiota disruption does not necessarily exacerbate seizure susceptibility.

Overall, while Jia et al provide intriguing evidence linking B. fragilis to seizure modulation, several limitations temper the conclusions. The small clinical sample size, heterogeneity in treatment response, and inconsistent microbiota changes across subgroups weaken causal inference. Together, these findings support a potential role for microbiota-targeted interventions in epilepsy, but underscore the need for larger, well-controlled, and additional mechanistically driven studies to determine whether specific microbial taxa or functions meaningfully influence seizure susceptibility.